Pharmaceuticals (May 2024)

Substance Addiction Rehabilitation Drugs

  • Shu Yuan,
  • Si-Cong Jiang,
  • Zhong-Wei Zhang,
  • Zi-Lin Li,
  • Jing Hu

DOI
https://doi.org/10.3390/ph17050615
Journal volume & issue
Vol. 17, no. 5
p. 615

Abstract

Read online

The relapse rate of substance abusers is high, and addiction rehabilitation adjunct drugs need to be developed urgently. There have been numerous reports on blocking the formation of substance addiction, but studies on drugs that can alleviate withdrawal symptoms are very limited. Both the dopamine transporter (DAT) hypothesis and D3 dopamine receptor (D3R) hypothesis are proposed. DAT activators reduce the extracellular dopamine level, and D3R antagonists reduce the neuron’s sensitivity to dopamine, both of which may exacerbate the withdrawal symptoms subsequently. The D3R partial agonist SK608 has biased signaling properties via the G-protein-dependent pathway but did not induce D3R desensitization and, thus, may be a promising drug for the withdrawal symptoms. Drugs for serotoninergic neurons or GABAergic neurons and anti-inflammatory drugs may have auxiliary effects to addiction treatments. Drugs that promote structural synaptic plasticity are also discussed.

Keywords